Price, one year
Price range
- Open
- ₹785.00
- High
- ₹797.45
- Low
- ₹778.00
- Previous close
- ₹785.15
- Volume
- 5.7 L
- Market cap
- ₹14,183 Cr
Key statistics
Results to 30 Jun 2026 · Consolidated- P/E (TTM)
- 12.4
- Price to book
- 1.5
- Return on equity
- 12.4%
- EPS (TTM)
- ₹63.89
- Book value / share
- ₹514.83
- Debt to equity
- 0.08
- Revenue (TTM)
- ₹3,485 Cr
- Net profit (TTM)
- ₹1,144 Cr
- Sales growth, YoY
- −44.7%
- Profit growth, YoY
- −57.0%
- Operating margin
- 30.2%
- Net margin
- 32.8%
- Sales CAGR, 3 years
- +14.6%
- Profit CAGR, 3 years
- +25.6%
- Promoter holding
- 49.39%
- Promoter shares pledged
- 0.00%
Shareholding pattern
% of shares| Holder | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|
| Promoters | 49.42 | 49.42 | 49.39 |
| Foreign institutions | 17.37 | 16.99 | 16.00 |
| Domestic institutions | 5.46 | 5.62 | 6.16 |
| Mutual funds | 1.72 | 1.92 | 2.25 |
| Retail and others | 23.33 | 23.41 | 23.86 |
Results and announcements
Latest results (quarter to 30 Jun 2026) filed 14 Aug 2026.
- 19 Oct 2026 · Press releasePress ReleaseNatco Pharma Limited has informed the Exchange regarding a press release dated October 19, 2026, titled "NATCO announces launch of Carboplatin Injection (generic of Paraplatin®) in the U.S. market".
Peers in Healthcare
All Healthcare stocks| Company | Price | Change |
|---|---|---|
| Sun Pharmaceutical IndustriesSUNPHARMA | ₹1,748.00 | −0.57% |
| Divi's LaboratoriesDIVISLAB | ₹8,950.00 | −2.31% |
| Torrent PharmaceuticalsTORNTPHARM | ₹4,524.40 | −1.97% |
| Zydus LifesciencesZYDUSLIFE | ₹1,129.40 | −0.49% |
| Apollo Hospitals EnterpriseAPOLLOHOSP | ₹7,730.00 | +1.65% |
| CiplaCIPLA | ₹1,338.00 | +0.53% |
| Laurus LabsLAURUSLABS | ₹1,970.00 | −1.62% |
| Dr. Reddy's LaboratoriesDRREDDY | ₹1,229.50 | −0.77% |
| Mankind PharmaMANKIND | ₹2,212.60 | −2.77% |
| Aurobindo PharmaAUROPHARMA | ₹1,571.70 | −2.43% |
Frequently asked questions
What is the share price of NATCO Pharma today?
NATCO Pharma (NSE: NATCOPHARM) was at ₹791.85 on 23 Oct 2026, a change of +0.85% from the previous close.
What are the 52-week high and low of NATCO Pharma?
Over the last 52 weeks NATCO Pharma traded between ₹773.60 and ₹1,226.80 (daily highs and lows on NSE on 23 Oct 2026).
What is the market capitalisation of NATCO Pharma?
About ₹14,183 Cr at the latest price, with a P/E of 12.4, a price-to-book of 1.5, a return on equity of 12.4%. Ratios use the company's latest reported results.
Who owns NATCO Pharma shares?
According to the shareholding pattern filed with the exchange at the end of the quarter to 30 Sep 2026, promoters held 49.39%, foreign institutions 16.00%, domestic institutions 6.16%.
Which sector and indices does NATCO Pharma belong to?
NSE classifies NATCO Pharma under Healthcare; it is a member of Nifty 500.
Follow NATCO Pharma with research you can verify. Add it to a watchlist, see screens and charts, and get calls from SEBI-registered research analysts with recorded track records.
Start free trial